Evaluation of Combination Chemotherapy Using High Dose Ara-C in Adult Acute Leukemia and Chronic Granulocytic Leukemia in Blastic Crisis
Research committees
Publication Information Expand/Collapse
2010
The effect of complete remission (CR) and CR with incomplete platelet recovery (CRp) on outcome in acute myeloid leukemia: a combined eastern cooperative oncology group (ECOG), Southwest Oncology Group (SWOG), and M.D. Anderson Cancer Center study
2000
Microsatellite Instability is not a defining genetic feature of acute myeloid leukemogenesis in adults: results of a retrospective study of 132 patients and review of the literature
1999
A phase II comparison of high dose ARA-C (HIDAC) vs HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia. A Southwest Oncology Group study.
1995
Trisomy 11: an association with stem/progenitor cell immunophenotype.
1992
Evaluation of combination chemotherapy using high dose ARA-C with and without mitoxantrone in the treatment of first relapse acute myeloid leukemia. A Southwest Oncology Group study.
The relationship of the stem cell phenotype and lineage commitment to the multidrug resistance phenotype in acute leukemia.
1991
Multidrug resistance in CD34+ acute leukemia correlates with non-lymphoid lineage.
Multiparameter analysis of acute mixed lineage leukemia: Correlation of aB/Myeloid immunophenotype and immunoglobulin and T-cell gene rearrangements with the presence of the Philadelphia chromosome translocation in acute leukemias with
1990
Multiparameter analysis of acute mixed lineage leukemia: Correlation of B/Myeloid immunophenotype and immunoglobulin and T-cell gene rearrangements with the presence of the Philadelphia chromosome translocation in acute leukemias with myeloid morphology.
1989
Increased risk of early death (ED) with high dose ara-C (HDAC)and m-AMSA compared to HDAC alone or HDAC and mitoxantrone (MITOX) inhigh risk nonlymphocytic leukemia (ANL)